Sort   by:  
 Page size 
UnknownNeoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis.
Not available
S-EPMC5679821 | biostudies-literature
UnknownElectronic health records and patient registries in medical oncology departments in Spain.
Not available
S-EPMC8390424 | biostudies-literature
UnknownIntrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.
Not available
S-EPMC5822682 | biostudies-literature
UnknownHigh Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer.
Not available
S-EPMC4746087 | biostudies-literature
UnknownBroad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists.
Not available
S-EPMC6493326 | biostudies-literature
UnknownDevelopment and validation of a sexual relations satisfaction scale in patients with breast cancer - "SEXSAT-Q".
Not available
S-EPMC6698031 | biostudies-literature
UnknownBOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study.
Not available
S-EPMC6925605 | biostudies-literature
UnknownA PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse.
Not available
S-EPMC5449267 | biostudies-literature
UnknownDerived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.
Not available
S-EPMC8875201 | biostudies-literature
UnknownLong-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Alamo IV registry.
Not available
S-EPMC10361852 | biostudies-literature
Sort   by:  
 Page size